- By:
- Buchsbaum, Jeffrey; Van Brocklin, Henry; Hernandez, Reinier ; O'Brien, Ellen; Hennkens, Heather M; Medvedev, Dmitri; Howell, Roger; Escorcia, Freddy; Dewaraja, Yuni; Jha, Abhinav; Kapadia, Anuj J; Agasthya, Greeshma; Rahmim, Arman; Saboury, Babak; Myhre, Kristian G; Davern, Sandra M
- Journal Name:
- Radiation Research
- Page Number:
- 75-79
- Volume:
- 204
- Issue Number:
- 1
- Publication Date:
- September 9, 2025
- View DOI Listing:
- https://doi.org/10.1667/RADE-25-00MR1.1
Abstract
The DOE-NIH Joint Workshop on Computational Modeling to Advance Novel Medical Isotopes for Radiotheranostics, held on September 27, 2024, brought together experts from government, academia, and industry to address critical challenges in radionuclide production and clinical translation. The workshop emphasized interdisciplinary collaboration, particularly between the Department of Energy (DOE) and the National Institutes of Health (NIH), to strengthen the domestic isotope supply, streamline regulatory pathways, and further integrate computational tools into radiopharmaceutical therapy (RPT). Key discussions explored the role of AI-driven modeling, machine learning, and digital twin technologies in optimizing dosimetry, dynamically personalizing treatments, and reducing time to clinical adoption. Advances in predictive computational modeling were highlighted as essential for improving radionuclide yield, purity, and synthesis efficiency. Regulatory considerations and equitable access were central themes, with participants advocating for harmonized global standards, adaptive trial designs, and expanded infrastructure for clinical implementation. DOE computational and production infrastructure was emphasized. Future priorities identified include increased investment in radionuclide production infrastructure, expanded workforce development in radiopharmaceutical sciences and computational modeling, and the creation of robust public-private partnerships. The workshop concluded that continued strategic collaboration and sustained resources will be vital for advancing next-generation radiotheranostics, ensuring safe and effective therapies accessible to all patients.